Avanos Medical Files 8-K on Officer Departures & Director Elections
Ticker: AVNS · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1606498
| Field | Detail |
|---|---|
| Company | Avanos Medical, INC. (AVNS) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $45,000, $60,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-compensation, director-election
Related Tickers: AVNS
TL;DR
AVNS 8-K: Leadership changes and new exec comp details filed.
AI Summary
On December 2, 2024, Avanos Medical, Inc. filed an 8-K report detailing the departure of certain officers and the election of new directors. The filing also includes information on compensatory arrangements for certain officers, and financial statements and exhibits.
Why It Matters
Changes in corporate leadership and officer compensation can signal shifts in company strategy or financial health, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive officers and directors, along with compensatory arrangements, can introduce uncertainty regarding future company direction and performance.
Key Players & Entities
- AVANOS MEDICAL, INC. (company) — Registrant
- December 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 5405 Windward Parkway Suite 100 South Alpharetta, Georgia 30004 (address) — Principal business address
FAQ
What specific officer positions have seen departures?
The filing indicates the departure of certain officers, but does not specify the exact positions in the provided text.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in the provided text.
What is the nature of the compensatory arrangements for certain officers?
The filing states that information regarding compensatory arrangements for certain officers is included, but the details are not specified in the provided text.
Are there any financial statements included with this filing?
Yes, the filing explicitly lists 'Financial Statements and Exhibits' as an item information.
What is the SEC file number for Avanos Medical, Inc.?
The SEC file number for Avanos Medical, Inc. is 001-36440.
Filing Stats: 822 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-12-03 12:21:18
Key Financial Figures
- $0.01 — nge on which registered Common Stock - $0.01 Par Value AVNS New York Stock Exchange
- $45,000 — will pay Mr. Machan a fixed fee of: (i) $45,000 per month for the period beginning on O
- $60,000 — nd ending on February 28, 2025 and (ii) $60,000 per month for the period beginning on M
Filing Documents
- avns-20241202.htm (8-K) — 30KB
- avnsform8k_12032024ex101.htm (EX-10.1) — 108KB
- avns-20241202_g1.jpg (GRAPHIC) — 15KB
- 0001606498-24-000094.txt ( ) — 323KB
- avns-20241202.xsd (EX-101.SCH) — 2KB
- avns-20241202_lab.xml (EX-101.LAB) — 23KB
- avns-20241202_pre.xml (EX-101.PRE) — 13KB
- avns-20241202_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 10.1 * Consulting Agreement dated December 2, 2024 by and between Avanos Medical, Inc. and Warren Machan 104 Cover Page Interactive Data File (embedded within the inline XBRL document) * Management contracts, compensatory plans or arrangements SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVANOS MEDICAL, INC. Date: December 3, 2024 By: /s/ Mojirade James Mojirade James Senior Vice President and General Counsel